Axa’s ChemoCentryx, Inc. CCXI Stock Holding History

Axa’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-39,700	Closed	-$2.46M	–	1369
2020 Q4	$2.46M	Sell	39,700 -7,800	-16%	-$447K	0.01%	818
2020 Q3	$2.6M	Sell	47,500 -6,200	-12%	-$334K	0.01%	769
2020 Q2	$3.09M	Buy	53,700 +25,300	+89%	+$1.38M	0.01%	735
2020 Q1	$1.14M	Buy	+28,400	New	+$1.21M	0.01%	832

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Axa's CCXI Position: Q1 2021 in Review

Axa sold out of ChemoCentryx, Inc. (CCXI) in Q1 2021, closing a stake of 39,700 shares — an estimated $2.46M sold.

Axa first reported a position in CCXI in Q1 2020 and held it in 4 quarters. The position peaked at $3.09M in Q2 2020. 183 funds tracked by Wall St. Rank hold CCXI as of Q1 2021.

Axa reported no remaining ChemoCentryx, Inc. position as of Q1 2021 after selling out during the quarter.
Axa sold 39,700 ChemoCentryx, Inc. shares in Q1 2021, an estimated $2.46M.
Axa first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 4 quarters.
Axa's ChemoCentryx, Inc. position peaked at $3.09M in Q2 2020.
183 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.